

Strategy In-Depth

14 March 2007 | 14 pages

Citigroup India Investor Conference 2007

Day One Highlights

- **About the event** — The Citigroup India Investor Conference 2007 (13-14 March Mumbai, 15-16 March New Delhi) got under way in Mumbai with more than 100 companies and nearly 300 registered institutional investors at the event. In addition to guest speaker speeches and company presentations, there are five sector side tours running concurrently through the week. The large turnout reflects continued interest in the Indian market.
- **Guest speaker takeaways** — The RBI Deputy Governor Usha Thorat spoke on banking and financial inclusion in India's economic growth. Deepak Parekh (Chairman- HDFC Group and Member - Investment Commission) talked about India's key growth drivers, risk factors, successes and laggards in the infrastructure sector, financial sector reforms and regulation.
- **Company takeaways** — In this note, we highlight takeaways from some of the companies present during the day (Asian Paints, Bharat Forge, Sun Pharma, United Spirits, etc).

Ratnesh Kumar¹

+91-22-6631-9888

ratnesh.kumar@citigroup.com

Tirthankar Patnaik¹tirthankar.patnaik@citigroup.com

See Appendix A-1 for Analyst Certification and important disclosures.

Citigroup Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD. Customers of the Firm in the United States can receive independent, third-party research on the company or companies covered in this report, at no cost to them, where such research is available. Customers can access this independent research at <http://www.smithbarney.com> (for retail clients) or <http://www.citigroupgeo.com> (for institutional clients) or can call (866) 836-9542 to request a copy of this research.

¹Citigroup Global Market India Private Limited

Guest Speaker Takeaways

Deepak Parekh, Chairman- HDFC Group, Member- Investment Commission

- **On Growth:** Noted that growth has been fuelled by industry and services, while agriculture has been a laggard. However, expects growth to sustain despite this, at 8.5-9% levels due to: (1) Strong Demographics, with a significant working population (60% of the population is below the age of 30, as compared with 47% in China, 40% in US, 32% in Japan), which in turn is fuelling a consumption-led boom; (2) An Investment Cycle Upturn, as reflected in the strong order books of companies; (3) a continued outsourcing advantage with 65% of global offshore IT functions off-shored to India. Finally, he noted that the growing confidence of the Indian entrepreneur has been a final ingredient in India's growth recipe.
- **Concerns Ahead.** Include sustaining the low-cost labor advantage; improving the quality of the talent pool, efforts toward agricultural reforms, politics, and inclusive growth across states.
- **Infrastructure Development:** Noted that growth across sectors has been varied. **Telecom** is making remarkable progress on the back of liberalization, as reflected in low tariffs, even while tele-density remains low, indicating scope for further growth. However, on the flipside, the **power sector** continues to remain a laggard, with the lack of privatization resulting in a high power deficit and growing T&D losses. However, he views the gradual privatization of the sector, coupled with recent bids for ultra-mega-power plants as positive developments. This has attracted investor interest since policy uncertainties have been the major hurdle in the power sector.
- **Using FX Reserves to finance infrastructure development:** Explained that the India Infrastructure Finance Company (IIFCL)- a government-owned SPV, will facilitate the process; so that the IIFCL will use FX reserves as a security to provide a guarantee to Indian companies, to raise money overseas. This would be non-inflationary, thus quelling concerns about the impact on money supply.
- **Financial Sector Developments:** Noted that the financial sector has been growing rapidly in recent years, but the sector's regulatory framework still needs to evolve as there are multiple regulators in different segments of the financial sector. Mentioned that while the equity investing has been deregulated, debt market remains relatively closed and underdeveloped. Also pointed out that the mortgage insurance market remains in an underdeveloped stage, since there is a lack of clarity on regulation.
- **Impact of higher interest rates on mortgages:** Pointed out that housing finance companies are taking steps to ensure a minimal impact by either increasing EMIs, raising the loan tenure, or allowing balloon payments.

Usha Thorat, Deputy Governor, Reserve Bank of India

- **Developments on the Monetary Front:** Strong capital inflows, coupled with FX reserves increasing by over US\$43bn in FY07 (more than double the growth in FY06), has resulted in a surge in liquidity and made monetary management difficult. In response to this, the RBI has hiked the cash reserve ratio (CRR) and also made adjustments in the liquidity adjustment facility

(i.e., imposed caps on the repo). Controlling inflation has also become a policy priority, and stressed that any anti-inflationary measure is in fact also an anti-poverty measure.

- **Focus on the 'need for inclusive growth'.** Pointed out that in order to ensure inclusive growth there are a number of issues that need to be addressed. These include: (1) Agricultural reforms to facilitate food security for the poor and also achieve the government's 11th Plan target of 4% growth in agriculture. This would encourage employment growth and an improvement in social sector indicators. (2) Infrastructure Development both through public and private sector investment; and (3) Correcting the current skewed growth path across states.
- **On the issue of financial sector inclusion.** Is of the view that currently, the penetration of the financial sector remains low; since despite strong growth in urban areas, farmers continue to depend on informal lending in rural areas. In order to ensure that agriculture comprises 18% of the credit portfolio, RBI is focused on improving credit delivery and the encouragement of Microfinance initiatives through self-help groups.

Company Highlights

Asian Paints (ASPN.BO - Rs695.65; 1L)

- **Paints market growth to remain strong** - According to the management, the paints market in India is highly resilient to downturns and growth has historically never fallen below double digits. Growth outlook remains robust, expected at 1.5x-2x GDP growth. Asian Paints as a market leader is best positioned to leverage off this growth.
- **Market leadership position allows pricing power** - Asian Paints' market leadership, strong brand and large distribution allow it to price its products at a premium. The company has taken price hikes every quarter over the last 4 quarters. According to the management, Asian Paints is among the highest-margin paints companies in the world.
- **International Business** - Asian Paints targets to be within the top 3 players in the Middle East and South Asian markets. In other international markets like the South Pacific and Caribbean, Asian Paints is looking to increase its market share by 1% per annum. Management expects international business to grow at 15% per annum.
- **Industrial Paints** - Management has guided at growth in excess of 20% for its industrial paints business. Its associate JV Asian Paints-PPG has recently acquired ICY India's auto refinish business, which is likely to make Asian PPG the leader in the auto-refinish segment.

Bharat Forge (BFRG.BO - Rs315.45; 1L)

- **Outsourcing opportunity remains strong** - driven by increasing cost pressures of OEMs in developed markets and also an escalating shift to forged parts from cast parts.
- **Revenue outlook** - Management forecasts 25% CAGR in revenues over the next 3-4 years. Margins are forecast to remain stable at current levels.

- **Outlook on Chinese venture** - has experienced teething problems over the past 18 months, which are temporal in nature. Expected to grow at an exponential pace for the next 3-4 years.
- **Investments in non-auto businesses** - management to invest USD75m to develop capacities for non auto businesses - targets revenues of USD250m in 3-4 years from this venture (targeting industries like oil and gas, aerospace). Substantially higher EBITDA margins (~30%) in this business than current businesses that have 24-26% margins.

Gammon (GAMM.BO - Rs316.25; 1L)

- Gammon is targeting revenues of Rs20bn in FY07E and expects to grow the top line in FY08E and FY09E by 35% annually. Management's internal targets are, however, higher with expectations of 50% annual growth and sales of Rs45bn by FY09E.
- Gammon's management expects EBITDA margins to stabilize at the 9-9.5% levels.
- Gammon does not expect to raise equity capital in the parent company till FY10E. The parent had a D:E of 0.2x at the end of FY06 and expects to incrementally fund growth through debt. Given the low current leverage, the company does not expect a negative view about the credit profile of the company on account of full tax accounting. Further, GIPL currently has no debt and can also leverage if needed.
- Gammon expects roads, ports, power transmission and urban infrastructure projects to be key growth drivers for the company.

Glenmark (GLEN.BO - Rs598.10; 1M)

- Glenmark reiterated its focus on building drug discovery R&D as the primary driver of growth, by leveraging the cash flows generated from the branded and generics business.
- The management threw more light on its biologics strategy – investment phase (in biosimilars and new biologics) over 2006-09 and first lead to come through by 2009.
- Recent deal with Dyax adds to its drug discovery effort in areas of oncology and inflammation – in licensing deal, under which Glenmark would provide 3 targets against which Dyax's wide library of MABs would be screened. The management expects to file IND for the first molecule by 2009 and look at further licensing out options in Phase I/II.
- Reiterated guidance that one more R&D licensing deal and one European acquisition would be concluded before end-FY07.

Gokaldas Exports (GOKL.BO - Rs246.50; 1M)

- **Growth triggers** — 1) Growing order books in exports and focus on diversifying customer base; 2) Expansions going on-stream; and 3) Exploring opportunities as a supplier to large branded retailers looking to scale up in the domestic market, management believes this will be margin accretive.
- **Enriching product mix, further** — Entered the structured suits market for men and women, which fetch higher prices (~\$40/pc) and superior margins –

recently set up a new facility in Bangalore. This apart, exploring export opportunity in new products like 1) industrial work-wear 2) innerwear and sleepwear products, looking to tie up with international lingerie brand and 3) Garments made from technical textiles.

- **Good progress on expansions** — Started production at Chennai SEZ plant and three new units in 3Q, production to ramp-up by 4Q – employs 54,000 people today. Plans to add more plants in Mysore (Apr'07), Tumkur (Apr'07) and Hyderabad (Sept'07) – this will increase present capacity of 26m pieces by ~35% to 36mn pieces by FY08.
- **Margin expansion to continue**— EBITDA margins likely to expand to 12% in FY07E. Focus on value addition, new customer additions, strong order flows drive volume growth with relatively stable pricing environment are key reasons for this – this trend is expected to continue.

Grasim (GRAS.BO - Rs2,053.90; 1L)

- **In cement (58% of sales)**, the ratio of blended cement should increase from 1.29 to around 1.35 by 4QFY08 partly due to the 1.3m tpa grinding unit in north India. This should help increase volumes and cut costs. Power costs will also fall by Rs2/unit as captive thermal power capacity increases by 50% to 90%, replacing diesel generating sets and grid power.
- **In VSF (28% of sales)**, Grasim plans to enter the speciality and non woven segment in the medium to long term for market enlargement. Demand in this segment is growing in Western countries and is currently being met by producers such as Lenzing of Austria. The planned capacity growth in VSF by 49,000 tpa (18%) will meet domestic and international demand.
- **Sponge iron (8% of sales)** margins continue to be low (6-10%) due to inadequate availability of natural gas. Capacity utilization should increase to about 80-90% from about 50% currently once it starts getting regular supplies of natural gas (likely by Dec 2007), and help to increase margins.
- **Dividend policy:** As far as possible, Grasim plans to maintain a payout ratio of 20-25% keeping in mind that interest rates are rising and their own strong capex plans of Rs47bn over the next two years particularly in case of cement for which it is expanding effective capacity by 10m tpa to 23m tpa by 1Q FY09.

GSPL (GSPT.BO - Rs48.60; 1M)

- **Rollout of network on schedule:** GSPL's pipeline network is on track, with the commissioning of the key Hazira-Vapi section of the network. Management is confident of doubling transmission volumes by CY09.
- **GSPL to benefit from infrastructure status for pipelines:** Future pipeline segments of GSPL will benefit from the new government policy on granting infrastructure status to cross-country pipelines.
- **Jamnagar pipeline to cater to future demand growth:** Besides demand from Reliance's refinery, GSPL's pipeline to Jamnagar will also be able to cater to demand from the proposed SEZ and Essar's refinery.

HDFC Bank (HDBK.BO - Rs959.65; 2L)

- **Asset quality remains stable** - no real changes over the recent past, including the unsecured portfolio, where there has been a level of concern that has been expressed in the market space.
- **Margins should also remain stable in the 3.8%-4% range** - HDBK has maintained its margins in both falling and rising rate environments, and that should not change. As far as CASA (Current and Savings Accounts) proportions are concerned, while the levels could go down and there could be a slight shift to term deposits, the low-share is offset by the higher returns on the existing CASA deposits.
- **Growth slowdown on account of higher rates** - HDBK has not seen any meaningful change yet, and it believes while industry growth levels should come down, at current GDP growth levels, it does not expect industry growth to fall below 22-23%. It believes it should be able to sustain its own asset growth rates of 25-30%, as in the past.
- **Agriculture lending** - unlikely to become a large proportion of the asset book; While it does see commercially viable lending opportunities in this segment, it is likely to remain selective in this space.
- Overall, it continues to believe the market should continue to expand and its own shares should continue to expand.

I-flex (IFLX.BO - Rs1,855.65; 3M)

- More and more banks opting for core banking solutions to continue driving good growth for I-flex's product business.
- Oracle has indicated in the past that it will keep I-flex listed for 5 years - when queried on the possibility of a delisting.

Jet Airways (JET.BO - Rs574.10; 3H)

- **Domestic operations** - Jet expects its domestic revenues to grow at a steady 16-17% CAGR next few years. Overall market forecast to grow at a faster pace - we expect ~22-25% CAGR for the next 3 years - driven by supply-side pressures. Domestic market yet to see signs of rationalization. Fleet expansion of LCCs (low-cost carriers) continues at an unabated pace.
- **Domestic margins** - short term, Jet expects its domestic yields to remain steady (despite onset of lean season), albeit we think this will be to some extent buffered by surcharges. Longer term, Jet forecasts its EBITDAR margins will stabilize at around 20% (vs. 13% currently).
- **International operations** - US operations hold the key to long-term profitability. Jet will initially target 3 cities in North America - New York, San Francisco and Toronto - with flights commencing in FY08E. Management expects the routes will turnaround in 12 - 18 months. Currently, all routes (including London) are profitable, though S. E. Asian routes (to Singapore and Kuala Lumpur) might again become unprofitable as wide-bodies replace 737s on these routes.
- **Fund raising** - equity issuance is on the anvil, quantum as yet remains uncertain. With current debt equity of around 2.4x (as at end Dec06), and a

capex plan of over USD2bn (most of which will be debt-funded), we believe that an equity infusion is inevitable.

L&T (LART.BO - Rs1,529.75; 2L)

- L&T targets to double revenues by FY10.
- L&T wanted to get into shipbuilding a long time back but were prevented from doing the same. This could be a big growth driver. In India for defense the Government shipyards take 5 years to build a ship whereas L&T could perhaps do the job in less than 2 years. Shipbuilding revenues will have a large defense component of ~ 20-30% in the future. In the long term, L&T wants to build a high technology shipyard so that it can do value-added work in India just as is done in Korea and Singapore and not just build large hulls as in China.
- Despite working on Delhi, Hyderabad and Bangalore airports, L&T has the capacity for more airport orders as capacity is not a constraint. Larger orders do not mean more manpower; it only means that a better project manager needs to be in charge. So if ticket sizes increase it helps L&T. Chennai, Calcutta and 35 non metro airports are likely to come up for bidding, and this could be a big growth area.
- On nuclear orders only L&T, HCC and Gammon are prequalified to do civil works. However, this area would be a growth opportunity only after a year or so. Whenever the opportunity comes up L&T is ready to capitalize.
- As volumes go up the defense orders will have a larger impact. Offset contracts should kick-in in the near future for orders given to Boeing, Airbus, EADs and the sale of F-16/F-18s and Hornets as the case might be.
- Investments in shipbuilding and power equipment manufacturing would not be of the big bang nature and will happen over a period of time. So the quantum is too small to bother with if the L&T balance sheet can absorb the same or not. L&T might issue FCCBs to fund the same.

Raymond (RYMD.BO - Rs341.30; 1L)

- **Thrust on branded retailing** — Plans to expand its premium brand portfolio and existing network of ~400 retail outlets to 480 stores in FY07E and 605 stores in FY08E, with retail space growing from 1.1m sq.ft by 30% over the next two years. Focus is primarily on Tier II and Tier III cities - management expects branded apparel revenues to grow at 20% over FY07-09E and higher EBITDA margins of 14-15% (vs. 6-7% of peers) given its premium positioning.
- **New ventures have started paying off** - With expansions at most of its joint ventures complete – the company is starting to witness good order flows for the high value shirting; production has stabilized at the woolen jacketing plant; rapid growth in export garment operations of suits, trousers, and shirts (all 100% subs) after initial hiccups.
- **Denim business still under pressure** — Outlook on denim business remains sluggish, while Indian operations are operating at 90% capacity utilizations with relatively stable prices (Rs.109/mtr) in India; JV's EU & US operations are experiencing a slowdown (70% utilization), expecting some recovery in 2HFY08.

- **New developments** - 1) Focus on inorganic initiatives for growth, particularly in women's wear; 2) exploring opportunities to unlock value for its real estate assets (140acres) in Thane, but expects a beginning on this in the next 2-3 years; 3) consolidate opportunities in engineering files and tools business, also open to spinning it off at a later date.

Reliance Communications (RLCM.BO - Rs416.70; 1M)

- **Wireless sub adds dip a temporary phenomenon:** While not ascribing any particular reason for the fall in sub adds in Feb-07, the company expects a recovery in the next 3-6 months with significant capacity addition in the existing 7 GSM circles (additional 6 mn lines) by April and re-instatement of CDMA capex (at least till the time there is clarity on GSM spectrum for the additional circles).
- **Release of GSM spectrum holding back RCOM:** Acknowledging this as a challenge for the industry, and especially for the potential new entrants, the company indicated that the timing of the GSM launch will be dependent on the release of GSM spectrum. However, the scale of investment will be significantly higher than the annual run-rate of the GSM peers as they will have to catch up on the network coverage.
- **Passive infrastructure sharing could create meaningful value:** RCOM confirmed the strong tailwinds on which the tower-sharing industry will be built. It believes that an average tenancy of 2-3 operators is easily possible and does not think their advantage will be diluted by offering their network to new entrants on a selective basis.
- **DTH/IPTV launch in 3Q07:** While there are still loose ends to be tied-up, RCOM is likely to advance its complementary services of DTH & IPTV in the next 6 months.

Sasken (SKCT.BO - Rs503.95; 1M)

- **"E-Series" target on track** – management had indicated that it would sign its first client in Q4FY07.
- Looking for acquisition in the telecom service provider space to add a new sub vertical in its core telecom vertical.

Satyam (SATY.BO - Rs452.15; 1M)

- **Demand environment remains strong** – It does not see any impact of the much talked about global slowdown as of now.
- **Pricing stable with an upward bias** – new clients coming in at 3-5% higher rates but the company is still assessing the weighted average impact for the next year.
- **On budget-related issues** – Satyam indicated that there will be no impact of MAT on reported earnings and the impact of ESOP is still not very clear; however, it is likely to pass it on to employees.

State Bank of India (SBI.BO - Rs980.70; 1L)

- **Growth:** Currently growing at 26%, and while higher interest rates could have an impact, it has not seen any impact as yet. It expects retail assets to grow at about 22%-24%.

- **Margins:** Recent increases in lending rates could actually push up margins in the near term, and 1Q08. Over the medium term, it believes margins could come down a little, to the 315-320bp levels.
- **Funding:** Continue to be comfortable on the funding front, and have been lenders in the call market for the last one year. It has not been participating meaningfully in bulk deposits that are being offered, unlike its associate banks.
- **Capital:** Is comfortable at over 12%, given the tier 2 bonds and hybrid capital that it has raised.

Sun Pharma (SUN.BO - Rs1,023.10; 3L)

- **R&D pipeline** - Sun Pharma has indicated that there are about 3 known targets for the NCE research. The most advanced molecule is an anti allergy molecule for which an IND has been filed in the US and phase II studies are ongoing. Sun Pharma is hosting a conference on March 15 to discuss the R&D pipeline in detail.
- **Product launches** in the domestic market will slow from the current levels over the next 3 years due to the onset of the patent regime.
- **No immediate target for Acquisitions** - The company indicated that there were no major targets for acquisition that could come through in the near term.
- **Budget Impact** - The current budget has no impact on the company's tax rate over the next 3 years.

Tata Chemicals (TTCH.BO - Rs189.00; 2M)

- **Soda Ash price outlook stable:** Tata Chem sees that strong Soda Ash prices are likely to sustain in the medium term. Tata Chem's Magadi (Kenya) expansion will be functioning from April-07 and will be a key driver for FY08 earnings growth.
- **Policy initiative on Fertilizers imminent:** Tata Chem expects that there will be clarity on the new fertilizer policy soon. It believes that the policy will be supportive of de-bottlenecking of Urea plants and its Barbala plant will be a beneficiary.
- **New initiatives could be future drivers:** Tata Chem will be investing Rs500m over the next 2-3 years in R&D in bio and nano-technology including bio-fuels.
- The company is also investing in building a back-end (including farm advisory, cold chain, packaging and wholesaling) for fresh farm products using the Tata Kisan Sansar Network.

Tech Mahindra (TEML.BO, Rs1492 - Not Rated)

- **Pricing stable with an upward bias**—However, the company believes that looking at T&M-based pricing will become less relevant and as hybrid models in pricing emerge.
- **Wage benchmarking currently ongoing (precursor to deciding on wage hikes for next year)** – however, with the present supply-side situation offshore

wages are expected to go up at least 15% and onsite wages by 2.5-3.5%, in management's view.

- Campus offers to 3,500 graduates made for next year.
- The large \$1b BT contract will start being visible in revenues from Q1FY08 and will take 6-8 quarters to hit peak rate. Margins on the new business to be in-line with company averages – as per the company.

United Phosphorus (UNPO.BO - Rs312.60; 1L)

- **Guidance of US\$750-770m revenues and 18-19% EBIDTA margins in FY08**—We highlight that EBIDTA margin guidance is after a one-time restructuring charge of cEur25m likely to be taken on rationalization of manufacturing and manpower; net of this, EBIDTA margins would be in-line with our estimates.
- **Cerexagri** - management expects an upswing in profitability to be much more rapid than we currently estimate - up to 20% from the current sub 10% in 18-20 months (our estimates build in 16% in FY09). We believe the higher guidance is on the back of the more aggressive rationalization measures planned by the company.
- **UPL would continue to look at acquisitions** - strategic fit rather than size is the key benchmark for the company. Reiterated that with growing scale, ability to invest in future growth initiatives - organic and inorganic - has improved considerably.

United Spirits (UNSP.BO - Rs757.60; 1L)

- **Growth, Margins to Remain Strong** - United Spirits' top-line growth is likely to remain strong, driven by strong volumes and improving product mix. Improving product mix changes are likely to drive further margin expansion.
- **Focus on top end increasing** - United Spirits is increasing its focus on the top-end whiskey segment. The management believes that Scotch whiskey is likely to emerge as a very important segment and are gearing up to increase presence in the segment. Its current Scotch brand 'Black Dog' will be extended to 8-year and 18-year-old variants.
- **Close to acquiring White & Mackay** - Due diligence on White & Mackay is on. White & Mackay will provide much needed bulk Scotch for the Indian operations - the company currently imports 12m liters of scotch for its blending requirements, which will only increase. Additionally, the company also mentioned that a shortage of Scotch whiskey is building up, and Scotch prices are going up.
- **White & Mackay will be value accretive** - Management stated that White & Mackay will be EPS accretive from year one. According to the management, of the total cost of acquisition, 70% is composed of the value of the Scotch inventory of White & Mackay. The acquisition will be funded through debt, of which only 50% will be on United Spirits' books, while the remaining will be non-recourse debt on White & Mackay's books.

Wipro (WIPR.BO - Rs581.90; 1L)

- **Confident on demand environment and pricing** – lack of clarity on the two large telecom clients (going through M&A) the only negative.

- **Confident on maintaining margins in a narrow band**—For the first 9mFY07 – margins have remained almost flat yoy despite ~120 bp negative impact of inorganic initiatives and wage hikes affected.
- **"String of Pearls" strategy on acquisition to continue** – Wipro plans to use a part of the cash on books to fill in gaps in service offerings.

Appendix A-1

Analyst Certification

I, Ratnesh Kumar, research analyst and the author of this report, hereby certify that all of the views expressed in this research report accurately reflect my personal views about any and all of the subject issuer(s) or securities. I also certify that no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

IMPORTANT DISCLOSURES

Customers of the Firm in the United States can receive independent, third-party research on the company or companies covered in this report, at no cost to them, where such research is available. Customers can access this independent research at <http://www.smithbarney.com> (for retail clients) or <http://www.citigroupgeo.com> (for institutional clients) or can call (866) 836-9542 to request a copy of this research.

A member of Ratnesh Kumar's team holds a long position in the shares of Tata Chemicals.

A member of Ratnesh Kumar's household holds a long position in the shares of Grasim Industries, Reliance Communications and State Bank of India.

Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Bharat Forge, Gammon India, Glenmark Pharmaceuticals, Gokaldas, Jet Airways (India) Ltd, Larsen & Toubro, Reliance Communications, Sasken Communication Technologies Ltd, Satyam Computers Services Ltd, State Bank of India, Sun Pharma, Tata Chemicals, United Phosphorus Ltd and United Sprits. This position reflects information available as of the prior business day.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of Bharat Forge.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Bharat Forge, I-Flex Solutions, Larsen & Toubro, State Bank of India and Tata Chemicals.

Citigroup Global Markets Inc. or its affiliates expects to receive or intends to seek, within the next three months, compensation for investment banking services from Gujarat State Petronet and Tata Chemicals.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Asian Paints, Bharat Forge, Gammon India, Glenmark Pharmaceuticals, Gokaldas, Grasim Industries, Gujarat State Petronet, HDFC Bank, I-Flex Solutions, Jet Airways (India) Ltd, Larsen & Toubro, Raymond Ltd, Reliance Communications, Sasken Communication Technologies Ltd, Satyam Computers Services Ltd, State Bank of India, Sun Pharma, Tata Chemicals, United Phosphorus Ltd and Wipro Ltd in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as investment banking client(s): Bharat Forge, Grasim Industries, Gujarat State Petronet, I-Flex Solutions, Jet Airways (India) Ltd, Larsen & Toubro, State Bank of India, Tata Chemicals and United Sprits.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, securities-related: Asian Paints, Bharat Forge, Gammon India, Glenmark Pharmaceuticals, Gokaldas, Grasim Industries, Gujarat State Petronet, HDFC Bank, I-Flex Solutions, Jet Airways (India) Ltd, Larsen & Toubro, Raymond Ltd, Reliance Communications, Sasken Communication Technologies Ltd, Satyam Computers Services Ltd, State Bank of India, Sun Pharma, Tata Chemicals and Wipro Ltd.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following company(ies) as clients, and the services provided were non-investment-banking, non-securities-related: Asian Paints, Bharat Forge, Gammon India, Glenmark Pharmaceuticals, Gokaldas, Grasim Industries, Gujarat State Petronet, HDFC Bank, I-Flex Solutions, Jet Airways (India) Ltd, Larsen & Toubro, Raymond Ltd, Reliance Communications, Sasken Communication Technologies Ltd, Satyam Computers Services Ltd, State Bank of India, Sun Pharma, Tata Chemicals, United Phosphorus Ltd and Wipro Ltd.

Citigroup Global Markets Inc. or an affiliate received compensation in the past 12 months from Grasim Industries, Gujarat State Petronet and United Sprits.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citigroup Investment Research product ("the Product"), please contact Citigroup Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citigroup Investment Research Ratings Distribution

Data current as of 31 December 2006

	Buy	Hold	Sell
Citigroup Investment Research Global Fundamental Coverage (3106)	43%	41%	15%
<i>% of companies in each rating category that are investment banking clients</i>	45%	41%	34%
India -- Asia Pacific (118)	58%	14%	28%
<i>% of companies in each rating category that are investment banking clients</i>	48%	50%	39%

Guide to Fundamental Research Investment Ratings:

Citigroup Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citigroup Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

OTHER DISCLOSURES

Within the past 5 years, Citigroup Global Markets Inc. or its affiliates has acted as manager or co manager of an offering of equity securities of Bharat Forge, I-Flex Solutions, Larsen & Toubro, Satyam Computers Services Ltd and Tata Chemicals.

Within the past 5 years, Citigroup Global Markets Inc. or its affiliates has acted as manager or co manager of an offering of fixed income securities of Bharat Forge, Grasim Industries, HDFC Bank and Larsen & Toubro.

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to Reliance Communications and Wipro Ltd. (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at www.citigroupgeo.com.)

Citigroup Global Markets Inc. or its affiliates beneficially owns 2% or more of any class of common equity securities of Gokaldas, Larsen & Toubro, Sasken Communication Technologies Ltd, Satyam Computers Services Ltd and Sun Pharma.

Citigroup Global Markets Inc. or its affiliates beneficially owns 5% or more of any class of common equity securities of Bharat Forge, Gammon India, Glenmark Pharmaceuticals, Reliance Communications, Tata Chemicals, United Phosphorus Ltd and United Sprints.

Citigroup Global Markets Inc. or its affiliates holds a long position in any class of common equity securities of Asian Paints, Bharat Forge, Glenmark Pharmaceuticals, Grasim Industries, Gujarat State Petronet, HDFC Bank, I-Flex Solutions, Jet Airways (India) Ltd, Raymond Ltd, Sasken Communication Technologies Ltd, Satyam Computers Services Ltd, State Bank of India, Sun Pharma, Tata Chemicals, United Sprints and Wipro Ltd.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the subject company(ies) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citigroup Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citigroup Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citigroup Wealth Advisors Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. If the Product was prepared by Citigroup Investment Research and distributed in Japan by Nikko Citigroup Ltd., it is being so distributed under license. Nikko Citigroup Limited is

regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Akasaka Park Building, 2-20, Akasaka 5-chome, Minato-ku, Tokyo 107-6122. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, which is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd., a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 lambton Quay, Wellington. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Papierów Wartościowych i Gield. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gashka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Taiwan through Citigroup Global Markets Inc. (Taipei Branch), which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citigroup Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would be illegal. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. Advice in the Product has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs.

© 2007 Citigroup Global Markets Inc. Citigroup Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citigroup and the Umbrella Device are trademarks and service marks of Citigroup or its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST
